Respiratory syncytial virus (RSV) is the leading global cause of respiratory infections in infants and the second most frequent cause of death during the first year of life. This highly contagious seasonal virus is responsible for approximately 3 million hospitalizations and 120,000 deaths annually among children under the age of 5 years. Bronchiolitis is the most common severe manifestation; however, RSV infections are associated with an increased long-term risk for recurring wheezing and the development of asthma. There is an unmet need for new agents and a universal strategy to prevent RSV infections starting at the time of birth. RSV is active between November and April in Italy, and prevention strategies must ensure that all neonates and infants under 1 year of age are protected during the endemic season, regardless of gestational age at birth and timing of birth relative to the epidemic season. Approaches under development include maternal vaccines to protect neonates during their first months, monoclonal antibodies to provide immediate protection lasting up to 5 months, and pediatric vaccines for longer-lasting protection. Meanwhile, improvements are needed in infection surveillance and reporting to improve case identification and better characterize seasonal trends in infections along the Italian peninsula. Rapid diagnostic tests and confirmatory laboratory testing should be used for the differential diagnosis of respiratory pathogens in children. Stakeholders and policymakers must develop access pathways once new agents are available to reduce the burden of infections and hospitalizations.

Azzari C., Baraldi E., Bonanni P., Bozzola E., Coscia A., Lanari M., et al. (2021). Epidemiology and prevention of respiratory syncytial virus infections in children in Italy. THE ITALIAN JOURNAL OF PEDIATRICS, 47(1), 1-12 [10.1186/s13052-021-01148-8].

Epidemiology and prevention of respiratory syncytial virus infections in children in Italy

Lanari M.;Parisi S.;
2021

Abstract

Respiratory syncytial virus (RSV) is the leading global cause of respiratory infections in infants and the second most frequent cause of death during the first year of life. This highly contagious seasonal virus is responsible for approximately 3 million hospitalizations and 120,000 deaths annually among children under the age of 5 years. Bronchiolitis is the most common severe manifestation; however, RSV infections are associated with an increased long-term risk for recurring wheezing and the development of asthma. There is an unmet need for new agents and a universal strategy to prevent RSV infections starting at the time of birth. RSV is active between November and April in Italy, and prevention strategies must ensure that all neonates and infants under 1 year of age are protected during the endemic season, regardless of gestational age at birth and timing of birth relative to the epidemic season. Approaches under development include maternal vaccines to protect neonates during their first months, monoclonal antibodies to provide immediate protection lasting up to 5 months, and pediatric vaccines for longer-lasting protection. Meanwhile, improvements are needed in infection surveillance and reporting to improve case identification and better characterize seasonal trends in infections along the Italian peninsula. Rapid diagnostic tests and confirmatory laboratory testing should be used for the differential diagnosis of respiratory pathogens in children. Stakeholders and policymakers must develop access pathways once new agents are available to reduce the burden of infections and hospitalizations.
2021
Azzari C., Baraldi E., Bonanni P., Bozzola E., Coscia A., Lanari M., et al. (2021). Epidemiology and prevention of respiratory syncytial virus infections in children in Italy. THE ITALIAN JOURNAL OF PEDIATRICS, 47(1), 1-12 [10.1186/s13052-021-01148-8].
Azzari C.; Baraldi E.; Bonanni P.; Bozzola E.; Coscia A.; Lanari M.; Manzoni P.; Mazzone T.; Sandri F.; Checcucci Lisi G.; Parisi S.; Piacentini G.; M...espandi
File in questo prodotto:
File Dimensione Formato  
s13052-021-01148-8.pdf

accesso aperto

Tipo: Versione (PDF) editoriale
Licenza: Licenza per Accesso Aperto. Creative Commons Attribuzione (CCBY)
Dimensione 1.72 MB
Formato Adobe PDF
1.72 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/855167
Citazioni
  • ???jsp.display-item.citation.pmc??? 46
  • Scopus 68
  • ???jsp.display-item.citation.isi??? 63
social impact